Eris Lifesciences has achieved closure for the acquisition of India brand business of Strides Shasun. In November, Eris Lifesciences had entered into definitive agreements with Strides Shasun for acquisition of Strides’ branded generics business in India for an aggregate cash consideration of Rs 500 crore. In terms of the agreement, Eris would acquire the marketing and distribution rights for the said portfolio of products in India while Strides will retain the global rights for these products.
Eris Lifesciences is engaged in manufacturing, marketing and selling of branded generics within the chronic and acute categories of the Indian Pharmaceutical Market.
